Altrius Capital Management Inc Acquires 631 Shares of AbbVie Inc. (NYSE:ABBV)

Altrius Capital Management Inc lifted its holdings in AbbVie Inc. (NYSE:ABBVFree Report) by 2.9% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 22,162 shares of the company’s stock after buying an additional 631 shares during the quarter. Altrius Capital Management Inc’s holdings in AbbVie were worth $2,986,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Kalos Management Inc. acquired a new position in shares of AbbVie during the first quarter worth approximately $26,000. Miller Wealth Advisors LLC lifted its holdings in AbbVie by 140.0% during the 2nd quarter. Miller Wealth Advisors LLC now owns 240 shares of the company’s stock worth $32,000 after buying an additional 140 shares in the last quarter. Sanctuary Wealth Management L.L.C. acquired a new position in AbbVie during the 2nd quarter worth $39,000. True Wealth Design LLC bought a new position in AbbVie in the 4th quarter valued at $39,000. Finally, PrairieView Partners LLC increased its stake in shares of AbbVie by 346.7% in the 2nd quarter. PrairieView Partners LLC now owns 335 shares of the company’s stock valued at $45,000 after buying an additional 260 shares during the period. Institutional investors and hedge funds own 67.86% of the company’s stock.

AbbVie Stock Down 0.2 %

ABBV stock traded down $0.30 during mid-day trading on Monday, hitting $138.00. 1,220,280 shares of the company were exchanged, compared to its average volume of 5,508,937. The company has a debt-to-equity ratio of 4.59, a quick ratio of 0.84 and a current ratio of 0.96. AbbVie Inc. has a 1-year low of $130.96 and a 1-year high of $168.11. The firm’s 50 day simple moving average is $146.58 and its 200 day simple moving average is $143.95. The firm has a market cap of $243.64 billion, a P/E ratio of 37.89, a P/E/G ratio of 2.45 and a beta of 0.51.

AbbVie (NYSE:ABBVGet Free Report) last issued its quarterly earnings data on Friday, October 27th. The company reported $2.95 EPS for the quarter, topping analysts’ consensus estimates of $2.86 by $0.09. The business had revenue of $13.93 billion for the quarter, compared to analyst estimates of $13.72 billion. AbbVie had a net margin of 11.81% and a return on equity of 152.70%. The firm’s quarterly revenue was down 6.0% on a year-over-year basis. During the same period last year, the business posted $3.66 earnings per share. On average, sell-side analysts predict that AbbVie Inc. will post 11.24 EPS for the current fiscal year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Tuesday, January 16th will be paid a dividend of $1.55 per share. This is a boost from AbbVie’s previous quarterly dividend of $1.48. This represents a $6.20 annualized dividend and a dividend yield of 4.49%. The ex-dividend date is Friday, January 12th. AbbVie’s dividend payout ratio (DPR) is currently 169.86%.

Wall Street Analyst Weigh In

Several research firms recently issued reports on ABBV. UBS Group decreased their price target on AbbVie from $157.00 to $150.00 and set a “neutral” rating on the stock in a report on Friday, October 20th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of AbbVie in a research note on Thursday, November 9th. They issued a “hold” rating and a $150.00 target price on the stock. assumed coverage on shares of AbbVie in a research note on Thursday, October 5th. They set a “strong-buy” rating for the company. Morgan Stanley raised their price objective on shares of AbbVie from $193.00 to $196.00 and gave the company an “overweight” rating in a research note on Monday, October 30th. Finally, Barclays raised shares of AbbVie from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $160.00 to $170.00 in a report on Monday, October 30th. Eight equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to, AbbVie presently has an average rating of “Moderate Buy” and a consensus target price of $167.69.

Read Our Latest Stock Analysis on AbbVie

About AbbVie

(Free Report)

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Beh├žet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies.

Further Reading

Want to see what other hedge funds are holding ABBV? Visit to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBVFree Report).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with's FREE daily email newsletter.